Here's what we'll cover
Here's what we'll cover
Maryland Just Made a Big Move on GLP-1 Affordability
If you've ever looked at an Ozempic price tag and felt your stomach drop, you're not alone. The list price for semaglutide can top $900 per month without insurance, putting it out of reach for millions of Americans who could genuinely benefit from it.
Maryland is now doing something about that. The state has announced it will cap out-of-pocket costs for Ozempic and related GLP-1 medications for state employees immediately, with a broader rollout to all Maryland residents planned for 2028. This is a meaningful shift, and it signals where the national conversation around GLP-1 affordability is likely heading.
What the Maryland Cap Actually Does
The cost cap limits how much a patient pays out-of-pocket for covered GLP-1 medications like Ozempic (semaglutide) and potentially others in the same drug class. For state employees enrolled in Maryland's public health plans, that cap is effective now.
The 2028 expansion is the larger headline. It means Maryland's legislature is signaling an intent to make this protection available to a much broader population, not just government workers. The exact structure, including which plans must comply and whether there are income or eligibility thresholds, is still being worked out through regulatory channels.
What this does not mean is that Ozempic becomes free. A cost cap limits your maximum exposure, not the total cost of the drug. Think of it like how some states cap insulin costs at $35 per month. You still pay, but you pay a predictable, limited amount.
Why This Matters Beyond Maryland
States often serve as testing grounds for national health policy. When states like Maryland, California, or Colorado take action on drug pricing, it creates pressure on federal lawmakers and private insurers to follow.
GLP-1 medications have become one of the most talked-about drug classes in the country. Wegovy (semaglutide for weight loss) and Mounjaro (tirzepatide) have shown dramatic results in clinical trials, with patients losing 15-22% of their body weight on average. But that efficacy is irrelevant if patients can't afford consistent access.
Maryland's move adds momentum to a growing national push to treat obesity as a chronic disease that deserves insurance coverage equal to conditions like diabetes and hypertension. Several other states are watching closely, and similar legislation is reportedly being considered in other legislatures.
Who Benefits Right Now
Maryland State Employees
If you work for the state of Maryland and are enrolled in a state health plan, you may already be eligible for the capped pricing. Your first step is to contact your benefits administrator or HR department and ask specifically about GLP-1 coverage under the new cap.
Ask these questions:
- Which GLP-1 medications are covered under the cap, and does it include both Ozempic and Wegovy?
- What is the specific dollar cap per month or per fill that applies to my plan?
- Does the cap apply to both brand-name and any generic or compounded versions?
- Is a prior authorization still required from my doctor before coverage activates?
Maryland Residents Not on State Plans
If you live in Maryland but aren't a state employee, the 2028 timeline still matters to you, but it doesn't help you today. However, there are real options available right now that can meaningfully reduce your costs.
What You Can Do Right Now to Lower Your GLP-1 Costs
You don't have to wait for 2028 to make semaglutide or tirzepatide more affordable. Here are the most practical paths available regardless of which state you live in.
Manufacturer Savings Cards
Novo Nordisk, the maker of Ozempic and Wegovy, offers savings programs that can reduce costs to as low as $25 per month for eligible commercially insured patients. These are not available to Medicare or Medicaid patients due to federal rules, but they can be a significant help for those with private insurance.
Compounded Semaglutide Through Telehealth
During the FDA shortage period, compounded semaglutide became widely available through licensed telehealth providers. While FDA-approved brand-name options remain the clinical standard, compounded versions offered through legitimate, licensed compounding pharmacies have allowed many patients to access similar treatment at a fraction of the cost, sometimes $200-$400 per month.
Availability of compounded semaglutide has changed as the FDA shortage status has been updated, so check current status with a licensed provider.
Telehealth Providers With Transparent Pricing
Some telehealth platforms have negotiated lower pricing or offer subscription models that bundle the consultation and medication costs. Comparing providers is one of the fastest ways to find savings. Check the Best Providers list at GLP-1.com to see up-to-date pricing and coverage options.
GLP-1 Coupons and Discount Programs
Third-party discount programs like GoodRx, and dedicated GLP-1 Coupons, can sometimes reduce the cash price at the pharmacy counter, even without insurance. The savings vary by location and pharmacy, so it pays to check before you fill.
How Maryland's Cap Compares to Other Cost-Reduction Approaches
The Bigger Picture on GLP-1 Insurance Coverage
One of the most persistent barriers to GLP-1 access is that many insurance plans, including Medicare until very recently, excluded obesity medications from coverage entirely. Medicare Part D coverage for Wegovy was only enabled after the FDA approved it for cardiovascular risk reduction in 2024, adding a new qualifying condition beyond weight loss.
Private insurers have been slow to follow, citing the high cost of covering a drug that a large portion of their insured population might use. Employers have been similarly cautious. Maryland's decision to act at the state level bypasses that hesitation for a significant group of people.
The debate isn't just about cost. It's about how the healthcare system classifies and treats obesity. When insurance covers bariatric surgery but not the medications that achieve comparable results with fewer risks, there's an inconsistency that advocates and physicians have been pushing back on for years.
Questions to Ask Your Doctor Before Starting or Continuing GLP-1 Treatment
Whether you're newly considering Ozempic or already mid-treatment, these are the most important conversations to have with your provider.
- Does my current insurance cover GLP-1 medications for my specific diagnosis, whether that is diabetes or obesity?
- Am I eligible for any manufacturer assistance programs given my insurance type and income?
- Is a prior authorization required, and can your office help me navigate that process and submit supporting documentation?
- If my insurance does not cover it, what is the most cost-effective option for my specific health situation?
- What happens medically if I have to pause treatment due to cost, and is there a safe way to manage that transition?
That last question is important. Research suggests that patients who stop GLP-1 medications often regain weight, which underscores why stable, affordable access matters, not just starting treatment.
No waiting list. No insurance needed.
Frequently Asked Questions
Who is eligible for the Maryland Ozempic cost cap right now?
Currently, the cost cap applies to Maryland state employees enrolled in state health insurance plans. All Maryland residents are expected to gain access to similar protections by 2028, though the specific eligibility rules for that broader rollout are still being finalized.
How much will Ozempic cost under the Maryland cap?
The specific dollar amount of the cap has not been publicly finalized as of the announcement. It is expected to function similarly to insulin cost caps in other states, limiting maximum out-of-pocket spending per fill or per month. Contact your state employee benefits administrator for the most current figures.
Does the Maryland cap apply to Wegovy and Mounjaro too?
The cap as reported focuses on GLP-1 medications used for diabetes and weight management, which could include Wegovy (semaglutide) and Mounjaro (tirzepatide). The specific list of covered drugs will depend on Maryland's formulary decisions. Check with your plan or HR department for the exact list.
What can I do to lower Ozempic costs if I don't live in Maryland?
Several options are available nationwide, including manufacturer savings cards from Novo Nordisk (for commercially insured patients), telehealth providers offering compounded semaglutide, and third-party discount programs like GoodRx. Comparing telehealth providers is also one of the most effective strategies for finding lower prices.
Will Medicare patients benefit from the Maryland cap?
The Maryland cap is structured through state insurance regulations, which generally do not cover Medicare directly since Medicare is a federal program. Medicare patients may benefit from separate federal-level coverage expansions, such as the recent addition of Wegovy for cardiovascular risk reduction under Medicare Part D.
Is compounded semaglutide still available in 2025 and 2026?
Compounded semaglutide availability has shifted as the FDA updates the shortage status of brand-name semaglutide. Some licensed compounding pharmacies still offer it, but availability and legality can vary. Always use a licensed, reputable provider and confirm current FDA guidance before seeking compounded versions.
The Bottom Line: Maryland's Move Is a Signal Worth Paying Attention To
Maryland's decision to cap GLP-1 costs is not just a local story. It reflects a growing recognition that medications like semaglutide and tirzepatide are serious, evidence-backed treatments for chronic conditions, and that pricing them out of reach for most patients is a public health problem, not just a personal finance issue.
If you are a Maryland state employee, act now. Contact your benefits administrator to confirm your coverage, find out the exact cap amount, and get your prescription process started if you haven't already.
If you live in Maryland but aren't on a state plan, mark 2028 on your calendar and stay engaged as the implementation details are released. Advocacy groups and your state legislators are the right channels to contact if you want to push for faster or broader implementation.
If you live outside Maryland, don't wait for your state to act. The gap between what GLP-1 medications cost and what patients can actually afford is a real barrier right now, but it's not insurmountable.
Here's where to start:
- Compare providers, since telehealth platforms vary widely on price, support, and which medications they offer. See the Best Providers guide on GLP-1.com for current, vetted options
- Check coupons and discount programs before every fill by taking 60 seconds to check available GLP-1 Coupons, since savings can add up to hundreds of dollars per year
- Talk to your doctor about your full range of options, from Ozempic to Wegovy to Mounjaro, since there are multiple medications, dosing pathways, and coverage scenarios worth exploring together
The cost of GLP-1 medications is a real and frustrating barrier, but the landscape is shifting. Maryland just proved that. And in the meantime, GLP-1.com is here to help you find every available savings opportunity today.
Always consult your physician or a licensed healthcare provider before starting, stopping, or changing any medication.